Fibrous Cap Thickness
Cross-source consensus on Fibrous Cap Thickness from 1 sources and 5 claims.
1 sources · 5 claims
Uses
Evidence quality
Other
Other
Other
Highlighted claims
- The REPRESS primary endpoint is absolute change in minimum fibrous cap thickness from baseline to 6 months within the matched target arterial segment. — PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study protocol for a multicentre randomised controlled trial
- If several stenotic vessels or plaques are present, REPRESS selects the plaque with the thinnest fibrous cap thickness for the target segment. — PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study protocol for a multicentre randomised controlled trial
- The trial especially focuses on fibrous cap thickness as an OCT-measured plaque characteristic during the first 6 months after ACS. — PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study protocol for a multicentre randomised controlled trial
- REPRESS sample-size assumptions expect an approximately 18 µm between-group difference in 6-month minimum fibrous cap thickness. — PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study protocol for a multicentre randomised controlled trial
- Prior HUYGENS and PACMAN-AMI data showed PCSK9 inhibitors added to statins improved plaque morphology over 1 year, including increased fibrous cap thickness. — PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study protocol for a multicentre randomised controlled trial